WASHINGTON (September 8, 2016)-- An animal study suggests that resistance to
tamoxifen therapy in some estrogen receptor positive breast cancers may originate from in utero exposure to endocrine disrupting chemicals.
Not exact matches
However, along with this seemingly linear storyline
in which retinoids block progesterone's promotion of CK5 + cells, previous work
in the lab of CU Cancer Center investigator Peter Kabos, MD, and others shows that breast cancers treated with anti-estrogen drugs like
tamoxifen or aromatase inhibitors show an increased population of CK5 + cells — it is as if these
therapies remove the roadblock of estrogen - dependent cells, leaving CK5 + cells to proliferate.
Of these variants, reported today
in the journals Nature and Nature Genetics, 65 are common variants that predispose to breast cancer and a further seven predispose specifically to oestrogen - receptor negative breast cancer - the subset of cases that do not respond to hormonal
therapies, such as the drug
tamoxifen.
«By paralleling
tamoxifen», says McCague, «hopefully minimal side effects will result, which is an important consideration
in the long - term
therapy of elderly patients.»
There are also preventive
therapies — such as
tamoxifen or the trial drug anastrazole — that interfere with the production of the hormone oestrogen, implicated
in many breast cancers.
Letrozole is approved by the FDA for the adjuvant treatment of early - stage breast cancer
in postmenopausal women who have already been treated with 5 years of
tamoxifen therapy.
It was used
in this study for the first time to study factors that cause estrogen receptor positive breast cancer to recur during
tamoxifen therapy.
Researchers further demonstrated that changes
in these genes were reversed by adding well - tolerated epigenetic modifying drugs, valproic acid and hydralazine, to
tamoxifen therapy regimen.
Now, all breast cancers are classified as estrogen - receptor positive or negative, an important guide to prognosis and
therapy, and medications, such as
tamoxifen, that can block the effects of estrogen have become important tools
in the treatment and possible prevention of breast cancer.
One study showed that when curcumin is used together with
tamoxifen in treating melanoma (the deadliest form of skin cancer), the combined
therapy selectively killed cancerous cells while preserving noncancerous cells.
New Drug
Therapies for Breast Cancer
Tamoxifen has been used for twenty years
in the treatment of advanced breast cancer.